324 related articles for article (PubMed ID: 30256826)
21. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
[TBL] [Abstract][Full Text] [Related]
22. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer.
Wijnen JT; Vasen HF; Khan PM; Zwinderman AH; van der Klift H; Mulder A; Tops C; Møller P; Fodde R
N Engl J Med; 1998 Aug; 339(8):511-8. PubMed ID: 9709044
[TBL] [Abstract][Full Text] [Related]
23. Identification of genetic variants for clinical management of familial colorectal tumors.
Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
BMC Med Genet; 2018 Feb; 19(1):26. PubMed ID: 29458332
[TBL] [Abstract][Full Text] [Related]
24. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing.
Chubb D; Broderick P; Frampton M; Kinnersley B; Sherborne A; Penegar S; Lloyd A; Ma YP; Dobbins SE; Houlston RS
J Clin Oncol; 2015 Feb; 33(5):426-32. PubMed ID: 25559809
[TBL] [Abstract][Full Text] [Related]
25. Canonical and uncanonical pathogenic germline variants in colorectal cancer patients by next-generation sequencing in a European referral center.
Poliani L; Greco L; Barile M; Dal Buono A; Bianchi P; Basso G; Giatti V; Genuardi M; Malesci A; Laghi L;
ESMO Open; 2022 Dec; 7(6):100607. PubMed ID: 36356413
[TBL] [Abstract][Full Text] [Related]
26. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
27. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M
Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive mismatch repair gene panel identifies variants in patients with Lynch-like syndrome.
Xavier A; Olsen MF; Lavik LA; Johansen J; Singh AK; Sjursen W; Scott RJ; Talseth-Palmer BA
Mol Genet Genomic Med; 2019 Aug; 7(8):e850. PubMed ID: 31297992
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome.
van der Klift HM; Mensenkamp AR; Drost M; Bik EC; Vos YJ; Gille HJ; Redeker BE; Tiersma Y; Zonneveld JB; García EG; Letteboer TG; Olderode-Berends MJ; van Hest LP; van Os TA; Verhoef S; Wagner A; van Asperen CJ; Ten Broeke SW; Hes FJ; de Wind N; Nielsen M; Devilee P; Ligtenberg MJ; Wijnen JT; Tops CM
Hum Mutat; 2016 Nov; 37(11):1162-1179. PubMed ID: 27435373
[TBL] [Abstract][Full Text] [Related]
30. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer.
Casey G; Lindor NM; Papadopoulos N; Thibodeau SN; Moskow J; Steelman S; Buzin CH; Sommer SS; Collins CE; Butz M; Aronson M; Gallinger S; Barker MA; Young JP; Jass JR; Hopper JL; Diep A; Bapat B; Salem M; Seminara D; Haile R;
JAMA; 2005 Feb; 293(7):799-809. PubMed ID: 15713769
[TBL] [Abstract][Full Text] [Related]
31. Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients.
Zumstein V; Vinzens F; Zettl A; Heinimann K; Koeberle D; von Flüe M; Bolli M
Swiss Med Wkly; 2016; 146():w14315. PubMed ID: 27152634
[TBL] [Abstract][Full Text] [Related]
32. The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family.
van Puijenbroek M; Nielsen M; Reinards TH; Weiss MM; Wagner A; Hendriks YM; Vasen HF; Tops CM; Wijnen J; van Wezel T; Hes FJ; Morreau H
Fam Cancer; 2007; 6(1):43-51. PubMed ID: 17039270
[TBL] [Abstract][Full Text] [Related]
33. Exome sequencing in diagnostic evaluation of colorectal cancer predisposition in young patients.
Tanskanen T; Gylfe AE; Katainen R; Taipale M; Renkonen-Sinisalo L; Mecklin JP; Järvinen H; Tuupanen S; Kilpivaara O; Vahteristo P; Aaltonen LA
Scand J Gastroenterol; 2013 Jun; 48(6):672-8. PubMed ID: 23544471
[TBL] [Abstract][Full Text] [Related]
34. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
35. Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer.
Esteban-Jurado C; Vila-Casadesús M; Garre P; Lozano JJ; Pristoupilova A; Beltran S; Muñoz J; Ocaña T; Balaguer F; López-Cerón M; Cuatrecasas M; Franch-Expósito S; Piqué JM; Castells A; Carracedo A; Ruiz-Ponte C; Abulí A; Bessa X; Andreu M; Bujanda L; Caldés T; Castellví-Bel S
Genet Med; 2015 Feb; 17(2):131-42. PubMed ID: 25058500
[TBL] [Abstract][Full Text] [Related]
36. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
37. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
[TBL] [Abstract][Full Text] [Related]
38. Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer.
Overbeek LI; Kets CM; Hebeda KM; Bodmer D; van der Looij E; Willems R; Goossens M; Arts N; Brunner HG; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
Br J Cancer; 2007 May; 96(10):1605-12. PubMed ID: 17453009
[TBL] [Abstract][Full Text] [Related]
39. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
40. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
